Full Press Release Details
Ultragenyx and Kyowa Kirin Announce Submission of Supplemental Biologics License Application to U.S. FDA for Crysvita (burosumab) for Tumor-Induced Osteomalacia (TIO).
RARE
Ultragenyx and Kyowa Kirin Announce Submission of Supplemental Biologics License Application to U.S. FDA for Crysvita (burosumab) for Tumor-Induced Osteomalacia (TIO)
Key Takeaway: Ultragenyx and Kyowa Kirin Announce Submission of Supplemental Biologics License Application to U.S. FDA for Crysvita (burosumab) for Tumor-Induced Osteomalacia (TIO)